Physician profile
James E Thompson
NPI 1194913533
$22,702.26
in general payments reported to CMS, 2019-2025
8 companies · $28.32 in 2025
The $28.32 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,592 · 2020: $173 · 2021: $10K · 2022: $7,244 · 2023: $168 · 2024: $193 · 2025: $28.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $21,947.62 | 2019-2023 | Vivitrol |
| Gilead Sciences, INC. | $218.05 | 2019-2023 | |
| W. L. Gore & Associates, INC. | $205.87 | 2019-2020 | |
| Braeburn INC. | $186.90 | 2023-2025 | Brixadi |
| Indivior INC. | $96.86 | 2019-2024 | Sublocade |
| Mentor Worldwide LLC | $18.58 | 2023 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.97 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.41 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.